Marie Bosslett, Assistant Editor

Experts discussed pediatric atopic dermatitis, treatment innovations, disease burden, and the latest topical and systemic therapies in a DermView video series.

When compared to corticosteroids alone, the combination therapy reduced disease severity and improved the skin barrier.

A new qualitative analysis revealed which type of content on acne is trending on the social media platform and how clinicians should respond.

“It's so exciting to see all these incredible female talents behind me. I want to give back and I want to help them climb on my shoulders and go higher,” Haws said.

In case you missed it, this week we had news about Arcutis’ sNDA for roflumilast in pediatric AD, the current clinical and aesthetic applications of snail mucin, positive results from the CHE delgocitinib trial in China, and more.

Share your thoughts by answering today’s poll and read about these popular aesthetic techniques for lips.

Review our content from the month of February that recognizes patients and clinicians with skin of color.

Learn more about the in-depth topics covered in the February 2025 print issue of Dermatology Times.

Belgian patients receiving biologics had faster response rates compared to phototherapy, systemic, and topical treatments.

Dermatology Times is looking back on the top stories in dermatology from the month of February.

After just 2 weeks of twice-daily use, a pediatric patient saw visually improved skin with no adverse events.

Nonsteroidal AD therapies are gaining attention due to their rapid effectiveness and ability to offer an alternative to long-term steroid use.

Haws offers advice to female clinicians about leadership, collaboration, and the future of the aesthetics industry.

A two-set Mendelian randomization analysis revealed a genetic correlation between depression and androgenetic alopecia.

A PDUFA target action date has been set for October 13, 2025.

This collective initiative gives Mindy Haws, MD, and her team the ability to reach more women in a way that gives back and helps them succeed.

The case-control Chinese study evaluated circumstances that have previously never been established as potential melasma causes.

Mindy Haws, MD, spoke to Dermatology Times about the new videos, podcasts, and other resources LIMITLESS offers for women at all stages of their careers.

Although more research is needed to fill this gap, sunscreen had the greatest success rates of all the prevention methods in this literature review.

In case you missed it, this week we had news about Arcutis’ new seborrheic dermatitis initiative with Odell Beckham Jr., Zabalafin’s IND for atopic dermatitis, dupilumab as a potential BP treatment, and more.

Satisfaction levels rose and recovery outcomes greatly improved with Cicaglocal compared to the placebo.

The combination treatment safely and quickly reduced laser-induced hyperpigmentation, especially on darker skin tones.

Symptoms of rosacea and dependence on oral medication were reduced in all 5 case studies.

Patients aged 6 to 12 had little to no adverse events and no pharmacokinetic abnormalities were noted.

The co-founder of PathAI and its PathAssist Derm tool believes AI is going to be incredibly valuable for dermatologists and dermatopathologists.

Alphyn’s therapy uniquely treats both the immune system and bacterial components of atopic dermatitis.

Positive results in melanin, erythema, wrinkles, texture, and periorbital dermal thickness were observed during the 8-week study.

Although the tool is currently designed for research use only, CEO Andy Beck, MD, PhD, is excited about its future in clinical dermatopathology.

“I think some key things that stand out to me are that it's safe, effective, backed by rigorous clinical data, and has very high patient satisfaction,” Watchmaker said about the new product.

Michael Rubio, PA-C, and Renata Block, MMS, PA-C discuss the complexities associated with practicing telemedicine, especially as a PA.